Global EOR platform Remote People earns top positions across Employer of Record, payroll outsourcing, HR SaaS, and recruitment software rankings for 2026.

NEW YORK, April 16, 2026 /PRNewswire/ — Remote People, a global Employer of Record (EOR) and HR platform, has been named the best Employer of Record for 2026 and ranked #1 EOR provider by Outsource Accelerator, the world’s leading global expansion and outsourcing resource. The ranking recognizes Remote People as the best Employer of Record for businesses hiring and managing distributed teams across 150+ countries without establishing local entities.

Why Remote People Is the Best Employer of Record in 2026

In its evaluation, Outsource Accelerator highlighted that Remote People’s EOR solution is ideal for businesses focused on “scaling distributed sales, support, and development teams globally while minimizing risk and administrative overhead.” The ranking reflects Remote People’s ability to combine enterprise-grade payroll, compliance, and HR features with cost efficiency, making it the best Employer of Record choice for startups, SMEs, and growth-stage companies.

Key factors that contributed to Remote People’s #1 EOR ranking include:

• Compliant employment contracts in 150+ countries with full local labor law coverage
• End-to-end global payroll processing, tax compliance, and benefits administration
• Enterprise-level HR management platform at price points accessible to growing companies
• Dedicated account management and onboarding support for distributed teams
• Recruitment, employment, and incorporation delivered through a single partner

Additional 2026 Rankings by Outsource Accelerator

In addition to being named the best Employer of Record, Remote People also secured top positions in several other 2026 rankings by Outsource Accelerator:

• Top 20 Payroll Outsourcing Companies
• Top 20 HR SaaS Companies
• 20 Best Recruitment Software

These placements reflect Remote People’s role as a global employment partner across recruitment, payroll, and compliance, and confirm its leadership across multiple HR technology categories.

CEO Statement

“This recognition from Outsource Accelerator is a strong validation of what we’ve been building,” said Antoine Boquen, CEO of Remote People. “From day one, our focus has been on delivering enterprise-level service at a price point that actually works for growing companies. Being ranked the number one Employer of Record for 2026, alongside recognition across payroll and HR software categories, shows that the market is responding to that approach.”

What Is Remote People? Company Overview

Remote People (formerly Horizons) is a global Employer of Record (EOR) platform headquartered in New York that helps companies recruit, employ, and incorporate in 150+ countries. EOR services start from $199 per month, with no setup fees or minimum commitments. The company covers the full hiring journey through:

• Employer of Record (EOR) services: compliant hiring in 150+ countries
• Global payroll processing: multi-currency, tax-compliant payroll across jurisdictions
• Benefits administration: locally compliant health insurance, pensions, and perks
• HR management: onboarding, contracts, leave tracking, and employee lifecycle tools
• International recruitment: in-house recruiters sourcing and screening talent across 150+ countries
• Company incorporation: entity setup in 150+ countries, typically in 2–6 weeks

Remote People serves startups, SMEs, and enterprises hiring international teams quickly and compliantly. Its combination of global coverage, transparent pricing from $199 per month, and enterprise-grade features is what earned it the title of best Employer of Record for 2026.

Industry Recognition

Beyond the Outsource Accelerator ranking, Remote People has earned over 200 awards across leading software review platforms, with a 4.8 out of 5 rating across 500+ verified reviews. This recognition reinforces Remote People’s position as the best Employer of Record in 2026.

Notable recognitions include:

• G2: Leader across 4 categories, #1 Easiest to Use, Best Support, High Performer, Best Estimated ROI, Easiest Setup, Best Usability, Users Most Likely to Recommend, and Top 100 Best Software Products (Winter 2026)
• Capterra: Best Ease of Use and Best Value (2026)
• Software Advice: Most Recommended and Best Customer Support (2026)
• Crozdesk: Trusted Vendor and Quality Choice
• Sourceforge: Top Performer

With more companies hiring across borders, recognition from Outsource Accelerator, G2, Capterra, Software Advice, and other review platforms reinforces Remote People’s status as a preferred partner for international hiring.

Frequently Asked Questions

What is the best Employer of Record for 2026?

Remote People has been named the best Employer of Record for 2026 and ranked #1 EOR provider by Outsource Accelerator, the world’s leading global expansion and outsourcing resource. The ranking reflects Remote People’s combination of enterprise-grade EOR services, cost efficiency, coverage in 150+ countries, and strong value for startups and SMEs.

What is Remote People?

Remote People (formerly Horizons) is a global Employer of Record (EOR) platform that helps businesses hire, manage, and pay employees in 150+ countries without setting up local entities. The company provides compliant employment contracts, global payroll, benefits administration, HR management, international recruitment through an in-house team of recruiters, and company incorporation in 150+ countries.

What services does Remote People offer?

Remote People offers Employer of Record (EOR) services, global payroll processing, benefits administration, HR management, international recruitment delivered by its in-house recruitment team, and company incorporation in 150+ countries. The company covers the full recruit, employ, and incorporate journey for businesses building distributed teams.

How many countries does Remote People cover?

Remote People enables businesses to hire and manage employees in 150+ countries worldwide, without the need to establish local legal entities in each jurisdiction.

About Remote People

Remote People (formerly Horizons) is a global Employer of Record (EOR) platform headquartered in New York that helps businesses hire, manage, and pay employees in 150+ countries without setting up local entities. The company covers the full recruit, employ, and incorporate journey, with EOR, global payroll, benefits administration, HR management, international recruitment through an in-house team of recruiters, and company incorporation. Remote People is named the best Employer of Record for 2026 by Outsource Accelerator (ranked #1 in the EOR category), is a G2 Leader across 4 categories, and holds over 200 awards across G2, Capterra, Software Advice, and other review platforms, with a 4.8/5 rating across 500+ verified reviews.

More Information

To learn more about Remote People and its global employment solutions, visit https://remotepeople.com.

BEIJING, April 16, 2026 /PRNewswire/ — Yiren Digital Ltd. (NYSE: YRD) (“Yiren Digital” or the “Company”), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and global markets, today announced its inclusion in the S&P Global Sustainability Yearbook (China Edition) 2026. Alongside this milestone, Yiren Digital was also honored with the “Industry Mover” distinction. The Yearbook is widely regarded as one of the most comprehensive annual publications evaluating corporate sustainability performance in China.

The recognition reflects Yiren Digital’s performance in the 2025 S&P Global Corporate Sustainability Assessment (CSA), where the Company scored 50 out of 100, placing Yiren Digital in the top decile of the “Diversified Financial Services and Capital Markets” industry globally as of October 24, 2025, reflecting a 12-point improvement over the prior year. For the 2026 China Edition, nearly 1,800 companies were assessed, with only approximately 190 selected for inclusion. Yiren Digital was further honored with the “Industry Mover” distinction, recognizing the Company as the strongest year-over-year ESG performer in its industry. The Company delivered meaningful gains across key ESG dimensions, including a 6-point increase in governance and a 10-point increase in social performance. S&P Global classified the Company’s overall data availability as High relative to industry peers.

“Our inclusion in the S&P Global Sustainability Yearbook (China Edition) 2026 reflects a conviction at the heart of our business: that a strong ESG strategy is inseparable from a strong fintech strategy,” said Mr. Ning Tang, Chairman and Chief Executive Officer of Yiren Digital. “AI-powered risk management and information security are not simply compliance boxes to check; they are how we earn and keep the trust of the customers we serve. Expanding financial inclusion for underserved borrowers and small business owners is central to our mission. This recognition underscores that sustainable value creation and commercial growth are mutually reinforcing, and we will continue to build on that foundation.”

Yiren Digital’s Key Achievements in the 2025 Corporate Sustainability Assessment

Yiren Digital delivered strong performance across both the Social and Governance & Economic dimensions. The Social Dimension was Yiren Digital’s strongest-performing dimension, with the Company achieving a score of 55/100, significantly ahead of the industry average of 24/100. The Governance & Economic Dimension also improved year over year, with performance exceeding industry averages across Risk & Crisis Management, Business Ethics and Information Security.

These results reflect the Company’s continued focus on embedding risk management, data security and financial inclusion into its core operating model.

Yiren Digital’s ESG Framework

Yiren Digital has established a three-tier ESG governance framework comprising a Board-level ESG Committee, management-level oversight, and an ESG working group. This structure integrates sustainability considerations into corporate strategy, business operations and risk management.

The Company has set targets to reach peak carbon emissions by 2030 and achieve net-zero greenhouse gas emissions from its own operations by 2060. In 2025, Yiren Digital published its second consecutive annual ESG Report alongside three ESG-related core policies, including its Occupational Health and Safety Policy, further strengthening its ESG disclosure framework. The Company’s ESG reporting now covers more than 90 sub-topics aligned with CSA evaluation criteria.

About Yiren Digital

Yiren Digital Ltd. is a leading fintech company specializing in digital consumer lending, insurance, and financial technology innovation across China and global markets. The Company leverages advanced artificial intelligence and emerging technologies to enhance customer experience, optimize capital efficiency, and expand financial inclusion. With the successful filing of the in-house developed Large Language Model Zhiyu, the substantial upgrade of its Magicube Agent platform, Yiren Digital is establishing a new growth engine to position itself as an AI-powered next-generation fintech leader. For more information, please visit https://ir.yiren.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident,” and similar expressions.

Forward-looking statements are based on management’s current expectations, assumptions, and assessments of current market and operating conditions. These statements involve inherent risks, uncertainties, and other factors, many of which are outside the control of Yiren Digital Ltd. (NYSE: YRD) (the “Company”), and which could cause actual results to differ materially from those expressed or implied in such statements.

Such risks and uncertainties include, but are not limited to, significant fluctuations in loan origination volumes, changes in credit performance and delinquency trends, variations in take rates and monetization efficiency, availability and cost of funding, and the Company’s ability to achieve its anticipated financial results or previously issued guidance.

In addition, the Company operates in a highly regulated industry in the People’s Republic of China (“PRC”), and its business is materially affected by the evolving regulatory framework applicable to credit facilitation, consumer finance, online lending-related services, data security, and financial risk management. Regulatory policies and implementation measures in these areas have undergone, and may continue to undergo, significant and rapid changes, including changes in interpretation and enforcement.

Such regulatory developments may include, but are not limited to, adjustments to risk retention and capital requirements, restrictions on pricing, interest rates, or service fees, enhanced consumer protection and compliance obligations, data privacy and cybersecurity requirements, and limitations on certain business models or partnership structures. These measures may materially impact the Company’s ability to originate loans, maintain relationships with funding partners, price its services competitively, or sustain historical revenue and profitability levels.

Furthermore, the timing, scope, and enforcement intensity of regulatory changes in the PRC are often uncertain and may vary across regions and over time. Such uncertainty may result in increased compliance costs, operational constraints, and strategic adjustments, and may also affect funding partner behavior, borrower demand, and overall industry liquidity.

In addition, shifts in regulatory policy and market expectations may adversely affect investor sentiment and capital market conditions for the industry, potentially resulting in reduced loan facilitation volumes, increased volatility in financial performance, and pressure on margins.

Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including, but not limited to, unexpected changes in regulatory policies or enforcement practices, macroeconomic conditions, borrower credit behavior, funding partner participation, competitive dynamics, and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission.

All forward-looking statements speak only as of the date of this press release. The Company undertakes no, and expressly disclaims any, obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required under applicable law.

FOSHAN, China, April 16, 2026 /PRNewswire/ — YIZUMI is strengthening its global manufacturing presence through continued engineering investment, expanding international operations, and a broader portfolio of advanced molding technologies. With capabilities spanning injection molding, die casting, rubber injection, automation, and thixomolding, the company is building a more connected platform for customers seeking precision, efficiency, and long-term production value.

This forward-looking direction will also take center stage at YIZUMI CONNECT 2026, which will be held from April 20 to 24, 2026 in Nanxun, Zhejiang, China, under the theme “Evolve Beyond Limits.” Designed around manufacturing technology, innovation, and industry collaboration, the event will serve as an important platform for showcasing YIZUMI‘s latest developments and broader strategic direction.

Expanding Global Manufacturing Strength

Founded in 2002, YIZUMI has grown into a world-class manufacturer of mid-to-high-end molding equipment and a leading provider of turnkey solutions. With over 5,000 employees and more than 140,000 machines operating globally, our production footprint spans nearly 800,000 square meters. This massive scale creates a robust foundation for advanced product development, manufacturing excellence, and international delivery.

That expanding global base is being matched by a larger industry presence. At YIZUMI CONNECT 2026, visitors will experience an over 61,000 m² smart factory, reflecting the company’s growing scale and its ambition to present a broader, more immersive showcase environment.

Engineering Innovation Driving Long-Term Growth

Technology remains central to YIZUMI’s long-term development. Average annual R&D investment exceeds CNY 200 million, and the company has developed more than 400 patented technologies across core equipment categories. An integrated product development model continues to support faster iteration, product upgrades, and the commercialization of new technologies.

This engineering foundation is helping YIZUMI move further into higher-value manufacturing segments, while also shaping the content of YIZUMI CONNECT 2026. The event will not only highlight equipment and solutions, but also strengthen industry dialogue through strategy launches, technology forums, and other programs focused on future manufacturing trends.

A Broader Platform for Modern Industry

YIZUMI’s product lineup now covers multiple major manufacturing processes, giving customers access to more complete production solutions under one brand. Major categories include injection molding machines, die casting machines, rubber injection molding machines, robotic automation systems, thixomolding solution, 3D-Printing, and Yi+Platform.

This multi-technology platform will be reflected throughout the event program. In addition to product and solution displays, YIZUMI CONNECT 2026 will feature a Summit Roundtable, a YIZUMI Strategy Launch, and 8 Innovation Zones, creating a more layered experience that combines product presentation, strategic communication, and themed technology showcases.

Next-Gen A6 Series for Intelligent Hydraulic Injection Molding

The Next-Gen A6 Series Advanced and Intelligent Injection Molding Machine reflects YIZUMI’s latest direction in hydraulic injection molding. Designed for modern production environments, the A6 Series combines intelligent control, energy efficiency, precision, and stable output in one platform.

Key features include:

• Clamping forces from 900 to 18,500 kN
• Built on the IPD 2.0 process
• Developed around intelligence, green performance, precision, and efficiency
• Designed for stable performance in demanding molding applications

FF Series for High-Precision Electric Injection Molding

The FF Series Electric Injection Molding Machine highlights YIZUMI’s strength in electric molding technology. This series is aimed at applications that require tighter process control, higher consistency, and smoother integration with automation systems.

Key features include:

• Clamping forces from 150 to 13,800 kN
• Supports seamless automation and intelligent integration
• Suited for parts with higher requirements in thickness, precision, and structural complexity
• Applied in medical, auto parts, 3C electronics sectors

LEAP Series for Advanced Die Casting

The LEAP Series Die Casting Machine represents YIZUMI’s continued push into higher-end die casting applications. Built for demanding production environments, the LEAP Series is designed to improve repeatability, control, and overall operating performance.

Key features include:

• Locking forces from 3,800 kN to 10,000 kN
• Upgrades in injection, control, locking, and energy-saving systems
• Equipped with Yi-Cast real-time closed-loop control technology
• Designed to improve overall equipment effectiveness in complex die-casting operations

YIZUMI CONNECT 2026 to Spotlight Innovation and Industry Connection

One of the signature moments of the event will be the debut of YIZUMI i-Factory (Nanxun), positioned as a major highlight of the overall program. Together with the Strategy Launch, the debut adds stronger forward-looking and industry-facing value to the event, extending it beyond a traditional equipment exhibition.

With its expanded exhibition area, featured launches, roundtable agenda, and innovation-focused displays, YIZUMI CONNECT 2026 is shaping up to be a high-visibility industry event that reflects both YIZUMI’s current capabilities and its next stage of development.

Looking Ahead

YIZUMI’s current trajectory points to a more connected and more technically advanced global manufacturing platform. A wider international presence, deeper engineering capability, and a steadily expanding product lineup are all pushing YIZUMI further into the global advanced manufacturing market.

As that momentum continues, YIZUMI CONNECT 2026 will offer customers, partners, and industry professionals a concentrated view of where the company is heading next—and how its technologies are evolving to support the future of manufacturing.

CONTACT: 
Roxy
Branding Management
Yizumi Holdings Co. Ltd.
Email: yizumicompany@gmail.com 
Website: https://www.yizumi.com/en

• The explosion of healthcare-focused LLMs and chatbots has given patients greater access to health information, but the accuracy of results and patient trust are falling short

• Built on the company’s Symptom Checker, Consult provides a clinically-validated and medically supported option to help guide patients to the right care

• Ubie’s platform has seen rapid adoption by consumers, with over 13 million monthly users (2 million in the US) in March 2026 and 25% month-over-month growth

NEW YORK, April 16, 2026 /PRNewswire/ — Ubie, an AI-driven and clinically vetted healthcare prediction platform that guides patients to the care they need, today announced the launch of Consult, the company’s doctor-approved, chat-based LLM developed specifically for healthcare. The new platform, which is built on top of the company’s clinically-validated Symptom Checker, is free to use and supports patients in deciding whether to self-manage or seek care, while also helping explain pre-existing diagnoses. The ultimate goal for the platform is to empower patients to take action and follow appropriate steps in their care, not to diagnose or prescribe.

It’s well known that patients are increasingly turning to LLM-based chatbots as a resource for health information. OpenAI, which developed ChatGPT, reports that 3 in 5 US adults use AI for health purposes. And while trust in AI is increasing, a majority of people (56%) are not confident that they can tell the difference between true and false AI responses. This raises serious concerns over the use of untested digital tools for self-diagnosis.

Recently, a large number of healthcare-focused LLMs have become available, but they have yet to prove trustworthy, especially for patients who might have serious medical conditions or need urgent care. Studies have shown the need for more rigorous trials before systems can be deployed for widespread use.

• Findings from a University of Oxford study show a major gap between the promise of LLMs and their actual usefulness in giving medical advice.
• In a different study, 1,298 participants were asked to use an LLM, such as ChatGPT or Meta’s Llama 3, for medical advice. Results show that the LLMs correctly identified medical conditions in fewer than 34.5% of cases.
• Outcomes from a study published in Nature show that ChatGPT Health “under-triaged” half of medical emergencies from clinically authored vignettes.

Ubie’s platform, which is used by more than 15 million people worldwide every month, is trained on more than 50,000 peer-reviewed publications, leverages a panel of more than 50 medical specialists for accuracy, and is connected to more than 1,800 healthcare provider organizations for real-world feedback.

Built on this foundation, Consult is designed to interact with patients through conversational dialogue, smart buttons, photo uploads, OTC advice, and trusted routing to appropriate medical attention. It can help patients get the information they need to make a care decision, such as monitoring conditions, visiting a doctor, going to the ER, or checking with a pharmacist for an over-the-counter medication.

“People are becoming accustomed to interacting with AI and chatbots on a daily basis, which is positive, but currently comes with too much risk,” said Kota Kubo, co-founder and co-CEO of Ubie. “Ubie Consult provides a trusted, highly accurate, medically-validated option that gives patients the information they need about their symptoms and ensures they get appropriate guidance and care.”

Chatbots and health-focused LLMs are helping to close gaps in healthcare access and equity by providing 24/7, low-cost, and scalable care alternatives, particularly for underserved, marginalized, or rural populations. But it’s important that digital tools are both accurate and trustworthy. Consult provides insights into symptoms and the best next steps for care before patients ignore potential issues or rush to urgent care or a specialist.

Ubie has seen rapid growth as more and more patients look for credible online sources of health information, with more than 2 million people in the US interacting with the platform in March 2026 and 25% month-over-month growth.

Consult was designed to closely mirror the structure and pacing of talking to a doctor, while ensuring patients don’t leave with more questions than they came with. Most importantly, the platform gives people answers they can trust because every pathway has been reviewed and validated by physicians.

Ubie’s Consult can be found at: https://ubiehealth.com/consult/

About Ubie

Ubie is a healthcare AI company powering clinical-grade, AI-first patient journeys. While general-purpose AI focuses on information, Ubie provides doctor-approved direction, guiding users safely from initial symptoms to actionable treatment. Backed by Google and global partners, Ubie combines proprietary disease-prediction AI with a HIPAA-ready “safety layer” to support digital front-door experiences and chronic disease management.

Globally, Ubie guides over 15 million monthly users, including 2 million in the U.S. In Japan, Ubie’s provider solutions support more than 1,800 healthcare organizations, clinical expertise now being scaled for U.S. health systems to provide the safest, most reliable bridge between patient symptoms and professional care.

Learn more about our vision and work at https://ubiehealth.com/company.

Media Contact

Rob Mazzini
Mazzini Public Relations
Rob@mazzinipublicrelations.com

• Piramal Pharma Solutions is a global leader in antibody-drug conjugate (ADC) development and manufacturing, leveraging over 20 years of specialized experience to support partners from early-stage to commercialization.
• Ajinomoto Bio-Pharma Services is a leading provider of biopharmaceutical manufacturing services and platform technologies, responsible for the development of AJICAP™, a set of proprietary technologies designed to facilitate the creation of site-specific ADCs and linkers.
• Piramal and Ajinomoto Bio-Pharma Services have entered a collaborative arrangement aimed at enhancing their customers’ ADC development and manufacturing programs.

MUMBAI, India and TOKYO, April 16, 2026 /PRNewswire/ — Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical manufacturing services and platform technologies, have announced a strategic collaboration.

Under this collaboration, Piramal will refer applicable customers seeking ADC manufacturing technology to Aji Bio-Pharma and AJICAP™. Aji Bio-Pharma will refer Piramal to customers as a potential CDMO for manufacturing products using AJICAP™ technology, supporting their programs across development and manufacturing.

Following the execution of this agreement, Piramal and Ajinomoto will enter into a separate Material Transfer Agreement (MTA) to allow the transfer of technology between companies. The MTA will equip Piramal with the expertise, capabilities, and personnel for it to manufacture AJICAP™-based products with precision and speed.

As the world’s first FDA-approved ADC CDMO, Piramal brings over two decades of experience to the field. The Company also pioneered commercial ADC manufacturing, earning it more than 15 years of specialized expertise. With a global network of state-of-the-art facilities, Piramal has developed hundreds of ADCs, completed thousands of batches, and currently manufactures multiple commercial ADCs. Ongoing expansions are increasing Piramal’s commercial-scale ADC capacity.

Ajinomoto’s AJICAP™ technology facilitates the development of site-specific ADCs and linker technologies through simple, efficient processes, empowering early-stage pharmaceutical developers to create ADCs with higher efficacy and lower toxicity. Pairing this innovative platform with Piramal’s clinical and commercial ADC GMP manufacturing expertise enables customers to accelerate development, streamline tech transfer, and simplify scale-up.

“We are excited to collaborate with Ajinomoto Bio-Pharma Services and enhance our ADC platform by offering manufacturing support for AJICAP™-based products,” said Peter DeYoung, CEO, Piramal Global Pharma. “With the implementation of these capabilities, we will accelerate innovation and expand access to this technology for our customers and their patients worldwide.”

“This collaboration with Piramal expands the ecosystem supporting AJICAP™ technology by connecting licensed customers with an experienced ADC manufacturing partner,” said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. “Through this collaboration, we aim to provide our customers with streamlined pathways and access to deep ADC expertise to advance high-quality programs from early development through commercial manufacturing.”

By combining AJICAP™’s site-specific conjugation technology with Piramal’s extensive development and manufacturing expertise, this collaboration will help customers deliver safe, effective, and precise ADC therapies with exceptional efficiency.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited’s associate company, Yapan Bio Private Limited.

For more information visit: Piramal Pharma Solutions | LinkedIn | Facebook | X

About Piramal Pharma Limited

Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics and vaccine segments.

For more information, visit: Piramal Pharma | LinkedIn

^{* Includes one facility via PPL’s minority investment in Yapan Bio.}

About Aji Bio-Pharma Services

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and United States, providing support across gene therapy, APIs, and both large and small molecule manufacturing. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including high potency APIs (HPAPI), continuous flow manufacturing, oligonucleotide synthesis, biocatalysis, Corynex® protein expression technology, antibody drug conjugations (ADC) and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our clients’ needs. Learn more: www.AjiBio-Pharma.com

Logo: https://laotiantimes.com/wp-content/uploads/2026/04/piramal_pharma_solutions_logo.jpg
Logo: https://laotiantimes.com/wp-content/uploads/2026/04/ajinomoto_logo.jpg